A Multiomics Study of Tumor Evolution Characteristics and Prognostic Model in Early-stage Non-small Cell Lung Cancer
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Disease-free survival (DFS)
研究概览
简要总结
The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.
详细描述
Lung cancer is the leading cause of cancer-related death globally. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and surgery is still the main treatment strategy. This study will determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old;
- •Early-stage NSCLC patients underwent radical surgical resection;
- •Sufficient tumor tissue and blood sample for study use;
- •Available clinical-pathologic data, imaging data and follow-up date;
- •Written informed consent.
排除标准
- •History of other malignant tumors;
- •Evidence of distant metastasis before surgery;
- •Insufficient tumor tissue or blood sample for study use;
- •Clinical-pathologic data, imaging data or follow-up date is not available;
- •Other judgments by the Investigator that the patient should not participate in the study.
结局指标
主要结局
Disease-free survival (DFS)
时间窗: Through study completion, an average of 2 years
Time from randomization to disease recurrence or death from any cause.
Overall survival (OS)
时间窗: Through study completion, an average of 2 years
Time from randomization to death from any cause.
次要结局
- Relationship between translational biomarkers and clinical outcome(Through study completion, an average of 2 years)
研究者
Jun Wang
Member of the Chinese Academy of Engineering
Peking University People's Hospital